RNAble

Modulating RNA Epitranscriptomics

Health Tech & Life Sciences
Active
Seed Ness Ziona, Israel Founded 2021
Last updated 2026-06-18
Total raised
Last: 2022-01
Stage
Seed
Founded
2021
Headcount
6
HQ
Ness Ziona, Israel
Sector
Health Tech & Life Sciences

About

RNAble is developing novel compounds that alter RNA stability through modulation of RNA epitranscriptomics for the treatment of specific cancers and rare genetic diseases with nonsense mutations.

RNA transcripts undergo modifications that are recognized by specific RNA-binding proteins dictating their stability. Professor Rotem Karni, RNAble inventor, discovered that targeting components of the RNA epitranscriptomic machinery with small molecules resulted in the stabilization of several RNAs, including unstable nonsense mutated transcripts which are degraded by the nonsense-mediated decay machinery.

This discovery opens the possibility of restoring the expression of mutated genes essential to rare diseases and suppressing the growth of specific cancers.

Funding history · 1 round · — total

Q&A

What is RNAble's primary focus?
RNAble is developing novel compounds to alter RNA stability by modulating RNA epitranscriptomics, aiming to treat specific cancers and rare genetic diseases with nonsense mutations.
When was RNAble founded?
RNAble was founded in June 2021.
Which investors participated in RNAble's funding round in January 2022?
In January 2022, Integra Holdings and RMGLOBAL Healthcare Fund Management participated in RNAble's funding round.
What is the current stage of RNAble?
RNAble is currently in the Seed stage.
What is the primary sector of RNAble?
RNAble's primary sector is Health Tech & Life Sciences.
Where is RNAble's headquarters located?
RNAble's headquarters is located in Ness Ziona, Israel.

Team · 1

Founder · Co-Founder & Advisor
LinkedIn ↗

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsGenes
Target customers
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesBiotechnology
Business model
B2B

Tags

cancerrare-diseasespharmaceuticalsgenetic-disorderscancer-therapy
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)